Our News

Affinia Therapeutics to Participate in Upcoming Investor and Industry Conferences

Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer

Affinia Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference

ASGCT 2024 | Machine-learning Guided Rational Design of Cardiotropic Capsids that Detarget Liver and DRG.

Affinia Therapeutics Presents Preclinical Data for Genetic Cardiomyopathy and Sporadic ALS Programs with Novel Cardiotropic and BBB-Penetrant AAV Capsids at the American Society of Gene & Cell Therapy 2024 Annual Meeting

ASGCT 2024 | Reduction of Atxn2, a Therapeutic Target for Sporadic ALS, in Non-human Primates Using a Novel, Intravenously Delivered AAV Capsid.

Discover what it’s like to be an Affinian

Changing the world for patients – powered by science